Novo Nordisk stock has staged a notable rebound after a difficult start to the year, helped by signs that its oral Wegovy product is gaining traction in the fast-growing GLP-1 obesity market. The Danish drugmaker had fallen behind Eli Lilly in investor enthusiasm as Lilly’s Zepbound and Mounjaro strengthened its position in weight-loss and diabetes treatments. But recent prescription data suggest Novo may be clawing back momentum, particularly as patients and physicians show growing interest in obesity pills rather than injections. Seeking Alpha reported that Novo shares had risen 22% over the prior three months despite earlier multiyear lows tied to a disappointing outlook.
Novo Nordisk Stock Rebounds as Oral Wegovy Gains Attention
Novo Nordisk’s recovery is closely tied to investor confidence in Wegovy, its flagship weight-loss treatment. Wegovy is best known as an injectable GLP-1 drug, but the launch of an oral version has added a new growth angle for the company. GLP-1 drugs mimic hormones involved in appetite regulation and blood sugar control, making them central to the obesity and diabetes drug boom.
The key issue for investors is not only whether Wegovy can keep growing, but whether the pill format can expand the overall market. Many patients prefer tablets over injections because pills are easier to store, easier to use, and less intimidating for first-time users. That matters because the obesity treatment market remains underpenetrated relative to the size of the eligible patient population.
Recent prescription tracking has strengthened the bullish case. Fierce Pharma, citing Citi analysis of IQVIA data, reported that Novo’s Wegovy pill had recorded roughly 142,000 prescriptions by mid-May, while the oral version accounted for about 31% of total Wegovy prescriptions. That suggests the pill is not merely a niche add-on but a meaningful part of the brand’s volume mix.
Eli Lilly Still Leads, but Foundayo’s Early Ramp Looks Slower
Eli Lilly remains a formidable competitor. Its obesity and diabetes portfolio includes Zepbound and Mounjaro, two brands that have helped the company command a premium valuation among large-cap healthcare stocks. Lilly also entered the oral obesity market with Foundayo, the brand name for orforglipron, which the company describes as a once-daily GLP-1 pill for chronic weight management.
However, early launch data indicate that Foundayo’s initial prescription uptake has trailed oral Wegovy. Reuters reported that Lilly’s pill reached 5,612 U.S. prescriptions in its third week after launch, while Novo’s Wegovy pill had generated more than 18,000 prescriptions in its first full week and later exceeded 134,000 prescriptions by its 16th week. Analysts cited by Reuters cautioned that it could take 8 to 12 weeks to better assess Foundayo’s real commercial momentum.
That caution is important. Early prescription data can be distorted by launch timing, payer coverage, direct-to-consumer channels, inventory availability, and physician sampling patterns. Lilly also has advantages that may not immediately show up in early weekly scripts, including brand strength, large-scale manufacturing investment, and its LillyDirect platform.
Still, the early comparison gives Novo something it badly needed: evidence that it can compete more effectively in oral obesity treatments, not just defend its existing injectable franchise.
Why the Wegovy Pill Matters for the GLP-1 Market
The oral GLP-1 race could change the economics of the entire obesity drug category. Injectable GLP-1 medicines have produced enormous demand, but they also come with barriers. Some patients dislike injections, some face supply constraints, and many struggle with insurance access or high out-of-pocket costs.
Oral drugs may help address part of that problem. Reuters reported that lower-cost oral weight-loss pills from Novo and Lilly are drawing interest from patients who previously used compounded alternatives, with doctors pointing to branded pills’ regulatory oversight and familiarity as advantages.
For Novo Nordisk, the Wegovy pill serves two strategic purposes. First, it gives the company a way to defend its obesity market share against Lilly. Second, it can potentially broaden the market by attracting patients who were reluctant to start injectable therapies. That second point is critical because the GLP-1 market may not be a zero-sum fight. If pills expand the number of patients seeking treatment, both Novo and Lilly could grow, even while competing aggressively.
Reuters also reported that Lilly said more than 8,000 doctors had prescribed Foundayo since its U.S. launch, with about one-third of those physicians not previously writing prescriptions for oral GLP-1 drugs. That supports the idea that oral products may be bringing new prescribers and patients into the category.
Insurance Coverage Could Shift the Competitive Balance
Coverage decisions by pharmacy benefit managers are another major variable for both Novo Nordisk stock and Eli Lilly stock. CVS Caremark recently moved to reinstate coverage for Lilly’s Zepbound and add Foundayo to its covered medications, potentially improving Lilly’s access after a period in which Novo had benefited from formulary dynamics. Reuters reported that CVS will reinstate Zepbound coverage starting October 1 and add Foundayo coverage sooner, with both Lilly and Novo products offered with equal consumer co-pays.
That development could help Lilly regain ground in the second half of the year. For Novo, it raises the stakes. Strong early oral Wegovy demand is positive, but sustained momentum will likely depend on payer access, pricing, manufacturing capacity, and patient retention.
Investors should also watch whether oral GLP-1 adoption cannibalizes injections or expands total prescriptions. If the pill mainly shifts existing Wegovy users from injections to tablets, the growth impact may be more limited. If it attracts new patients who would otherwise avoid treatment, Novo’s revenue opportunity could be significantly larger.
What Investors Should Watch Next
For healthcare investors, the Novo Nordisk versus Eli Lilly race now hinges on several measurable indicators. Weekly prescription trends will remain important, especially as Foundayo moves beyond its earliest launch phase. Market share within obesity GLP-1 prescriptions will also matter, as will the split between injectable and oral formulations.
Earnings reports will be another key checkpoint. Investors should focus on obesity revenue growth, gross margin commentary, supply capacity, and management guidance. In this context, “guidance” refers to a company’s forecast for future sales, profit, or operating trends. Any upward or downward revision could move both Novo Nordisk stock and Eli Lilly stock sharply.
Valuation is also part of the story. Lilly has enjoyed a premium because of its stronger recent execution and broad investor confidence in its pipeline. Novo’s rebound suggests the market is reassessing whether that gap became too wide. But a rally based on early prescription data still needs confirmation from revenue, market share, and operating performance.
FAQ
Why is Novo Nordisk stock rising?
Novo Nordisk stock has rebounded as investors respond to stronger prescription momentum for the Wegovy pill and signs that the company may be regaining ground in the GLP-1 obesity market.
What is the Wegovy pill?
The Wegovy pill is an oral version of Novo Nordisk’s weight-loss treatment. It targets the GLP-1 pathway, which helps regulate appetite and metabolic signals.
Is Eli Lilly still ahead of Novo Nordisk?
Eli Lilly remains a major leader in obesity and diabetes drugs, but Novo’s oral Wegovy launch has improved its competitive position. The race remains highly dependent on prescriptions, payer access, pricing, and supply.
What should investors watch in the GLP-1 market?
Key metrics include prescription growth, insurance coverage, oral versus injectable demand, earnings guidance, supply capacity, and market share between Novo Nordisk and Eli Lilly.
Disclaimer: This article is for informational purposes only and does not constitute financial advice. Always conduct your own research before making any investment decisions.
